Segment and Geographic Information

12 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Segment and Geographic Information

Segment and Geographic Information

The Company manages its business and operations as one segment and is focused on advancing the treatment of acute and intensive care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. Revenues reported to date are derived primarily from the sales of Angiomax in the United States.

The geographic segment information provided below is classified based on the major geographic regions in which the Company operates.

	Years Ended December 31,
	2014				2013				2012
	(In thousands)
Net revenue:
United States	$	687,830	95.0	%	$	629,459	91.5	%	$	512,044	91.7	%
Europe	32,859		4.5	%	50,419		7.3	%	38,517		6.9	%
Other	3,719		0.5	%	7,986		1.2	%	8,027		1.4	%
Total net revenue	$	724,408			$	687,864			$	558,588

	Years Ended December 31,
	2014				2013
	(In thousands)
Long-lived assets:
United States	$	1,218,370	99.3	%	$	1,139,210	99.2	%
Europe	8,899		0.7	%	9,035		0.8	%
Other	15		—	%	22		—	%
Total long-lived assets	$	1,227,284			$	1,148,267